ESMO Asia 2016: First-in-class inhibitor of FGFR2 shows promising results in preclinical studies

December 21st, 2016 Novel allosteric fibroblast growth factor receptor 2 (FGFR2) inhibitor alofanib has potent antitumor and antiangiogenic activity, according to results of preclinical studies presented at the ESMO Asia 2016 Congress in Singapore, 16-19 December 2016 (Abstract 151O). These data provide strong rationale for evaluation of compound in...